datopotamab deruxtecan 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antitumor, monoclonal antibodies 5762 None

Description:

MoleculeDescription

Molfile

Synonyms:

  • datopotamab deruxtecan
  • datroway
  • datopotamab deruxtecan-dlnk
Datopotamab deruxtecan-dlnk, is a Trop-2-directed antibody-drug conjugate. The antibody is a humanized anti-Trop2 IgG1.
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

None

Approvals:

DateAgencyCompanyOrphan
April 4, 2025 EMA Daiichi Sankyo Europe GmbH
Jan. 1, 2025 FDA Daiichi Sankyo (AstraZeneca)
Dec. 12, 2024 PMDA Daiichi Sankyo Company, Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 305.36 74.79 80 338 156535 90471494
Stomatitis 157.28 74.79 55 363 274643 90353386
No adverse event 85.53 74.79 25 393 67957 90560072

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Disease progression 234.36 79.09 64 245 243970 110345020

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FX35 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
Other monoclonal antibodies and antibody drug conjugates
MeSH PA D000074322 Antineoplastic Agents, Immunological
MeSH PA D000970 Antineoplastic Agents
MeSH PA D007155 Immunologic Factors
MeSH PA D018796 Immunoconjugates
CHEBI has role CHEBI:35610 antineoplastic agent

Related Drugs by ATC class:

L01FX Other monoclonal antibodies and antibody drug conjugates 29 drugs
amivantamabbelantamab mafodotinblinatumomabbrentuximab vedotincatumaxomabelotuzumabelranatamabenfortumab vedotinepcoritamabgemtuzumab ozogamicinglofitamabipilimumab show all 29 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Metastatic hormone receptor-positive cancer; HER2-negative breast cancer indication 417181009




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Tumor-associated calcium signal transducer 2 Tumour-associated antigen BINDING AGENT EC50 9.13 DRUG LABEL DRUG LABEL

External reference:

IDSource
2238831-60-0 SECONDARY_CAS_RN
CHEMBL4297939 ChEMBL_ID
C000731951 MESH_SUPPLEMENTAL_RECORD_UI
13304 IUPHAR_LIGAND_ID
DB16410 DRUGBANK_ID
4043693 VANDF
C5432272 UMLSCUI
CHEBI:757370 CHEBI
11218 INN_ID
D12359 KEGG_DRUG
392118 MMSL
43685 MMSL
d10252 MMSL
019980 NDDF
GD2OWY1DTK UNII
2703033 RXNORM

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
DATROWAY HUMAN PRESCRIPTION DRUG LABEL 1 65597-801 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 100 mg INTRAVENOUS BLA 32 sections